Aurora Cannabis Invests in EU Facility Upgrades to Boost Production and Quality

### Aurora Cannabis Invests in European Expansion to Enhance Production Capabilities

Aurora Cannabis Inc., a leading Canadian medical cannabis company, announces a strategic investment aimed at significantly upgrading its EU-GMP manufacturing facility located in Leuna, Germany. Over the next five years, this initiative is designed to elevate the company's operational standards and enhance flower growth capacity, product quality, and cost efficiency. Alex Miller, the Executive Vice President of Operations, highlights that these upgrades are essential not only for achieving operational excellence but also for positioning Aurora to meet the increasing demand for premium medical cannabis across Europe. This investment underscores Aurora's commitment to maintaining high standards in manufacturing while addressing the evolving needs of its patient base.

The planned enhancements include the addition of new grow rooms, as well as upgrades to irrigation and lighting systems. Additionally, Aurora is set to implement advanced drying techniques that are expected to improve the overall quality of its cannabis products. As one of only three licensed cultivation facilities in Germany, Aurora Leuna plays a crucial role in supplying locally grown medical cannabis under the IndiMed brand. The facility also intends to introduce a wider variety of cultivars from its expansive genetics library, further diversifying its product offerings in a market that is rapidly expanding in patient numbers and product demand.

This investment not only emphasizes Aurora's operational capabilities but also reflects its broader vision for growth in international markets. By adopting superior global manufacturing practices, the company reinforces its position as a key player in the European medical cannabis landscape. With a focus on science, innovation, and quality, Aurora Cannabis continues to lead the industry, providing a wide range of cannabis products for both medical and consumer markets. The company's commitment to enhancing its manufacturing capabilities is a significant step toward fulfilling its long-term goals for operational excellence.

In addition to its European initiatives, Aurora Cannabis operates globally, with a presence in Canada, Australia, and New Zealand. The company boasts a diverse portfolio of brands, including adult-use offerings like Drift, San Rafael '71, and Daily Special, as well as medical brands such as MedReleaf and CanniMed. Furthermore, Aurora holds a controlling interest in Bevo Farms Ltd., a leading supplier in the agricultural plant sector, which complements its core business in cannabis.

This strategic investment signifies Aurora's proactive approach to scaling operations and adapting to market demands, ultimately aiming to solidify its leadership position in the competitive medical cannabis industry.